Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019084 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019084: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019084 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019084, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatment for advanced cancer. PURPOSE: Phase II trial to study the effectiveness of a vaccine made with the patients' white blood cells mixed with tumor proteins in treating patients who have advanced cancer.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- BIOLOGICAL sargramostim
- BIOLOGICAL ras peptide cancer vaccine
- BIOLOGICAL mutant p53 peptide pulsed dendritic cell vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-02 |
| Est. Completion | 2003-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00019084
The ClinicalTrials.gov registry entry for NCT00019084 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which therapeutic autologous lymphocytes is the first listed.
NCT00019084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00019084 about?
NCT00019084 is a clinical study titled "Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer". RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may be an effective treatmen...
What is the current status of trial NCT00019084?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-02. Estimated completion is 2003-05.
What interventions are being tested in trial NCT00019084?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), sargramostim (BIOLOGICAL), ras peptide cancer vaccine (BIOLOGICAL), mutant p53 peptide pulsed dendritic cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019084?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.